Proprietary AI analyst is now available
- Public Comps
- Personalis
Personalis Valuation Multiples
Discover revenue and EBITDA valuation multiples for Personalis and similar public comparables like Eckert & Ziegler, Azenta, OPKO Health, Absci and more.
Personalis Overview
About Personalis
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
Founded
2011
HQ

Employees
229
Website
Financials (LTM)
EV
$907M
Valuation Multiples
Start free trialPersonalis Financials
Personalis reported last 12-month revenue of $74M and negative EBITDA of ($91M).
In the same LTM period, Personalis generated $14M in gross profit, ($91M) in EBITDA losses, and had net loss of ($93M).
Revenue (LTM)
Personalis P&L
In the most recent fiscal year, Personalis reported revenue of $70M and EBITDA of ($71M).
Personalis is unprofitable as of last fiscal year, with gross margin of 23%, EBITDA margin of (102%), and net margin of (117%).
Financial data powered by Morningstar, Inc.
Personalis Stock Performance
Personalis has current market cap of $1B, and enterprise value of $907M.
Market Cap Evolution
Personalis' stock price is $10.52.
Personalis share price decreased by 7.7% in the last 30 days, and increased by 60.4% in the last year.
Personalis has an EPS (earnings per share) of $-0.78.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $907M | $1B | 7.9% | -7.7% | 65.1% | 60.4% | $-0.78 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPersonalis Valuation Multiples
Personalis trades at 12.3x EV/Revenue multiple, and (10.0x) EV/EBITDA.
EV / Revenue (LTM)
Personalis Financial Valuation Multiples
As of June 19, 2026, Personalis has market cap of $1B and EV of $907M.
Personalis has a P/E ratio of (11.8x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Personalis Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Personalis Margins & Growth Rates
Personalis grew revenue by 13% and EBITDA by 49% in the last fiscal year.
In the most recent fiscal year, Personalis reported gross margin of 23%, EBITDA margin of (102%), and net margin of (117%).
Personalis Margins
Personalis Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Personalis Operational KPIs
Personalis' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.5M for the same period.
Personalis' Rule of 40 is (121%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Personalis' Rule of X is (101%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Personalis Competitors
Personalis competitors include Eckert & Ziegler, Azenta, OPKO Health, Absci, GemPharmatech, Vazyme Biotech, Suzhou Sepax Technologies, VCANBIO, Takara Bio and SEEGENE.
Most Personalis public comparables operate across Diagnostics & Genomics, Life Sciences Tools, BioTech, DeepTech and Longevity.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 2.8x | 2.8x | 9.4x | 9.5x | |||
| 1.3x | 1.3x | 11.3x | 12.1x | |||
| 1.9x | 2.0x | (27.3x) | (8.6x) | |||
| 368.7x | 251.5x | (10.0x) | (9.2x) | |||
| 8.8x | 8.1x | 27.1x | 24.3x | |||
| 4.5x | 4.2x | 40.1x | 26.1x | |||
| 19.4x | 17.2x | 46.9x | - | |||
| 4.8x | - | 20.6x | - | |||
This data is available for Pro users. Sign up to see all Personalis competitors and their valuation data. Start Free Trial | ||||||
Personalis VC Funding History
Before going public, Personalis raised $55M in total equity funding, across 2 rounds.
Personalis Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Personalis
| When was Personalis founded? | Personalis was founded in 2011. |
| Where is Personalis headquartered? | Personalis is headquartered in United States. |
| How many employees does Personalis have? | As of today, Personalis has over 229 employees. |
| Who is the CEO of Personalis? | Personalis' CEO is Christopher Hall. |
| Is Personalis publicly listed? | Yes, Personalis is a public company listed on Nasdaq. |
| What is the stock symbol of Personalis? | Personalis trades under PSNL ticker. |
| When did Personalis go public? | Personalis went public in 2019. |
| Who are competitors of Personalis? | Personalis main competitors include Eckert & Ziegler, Azenta, OPKO Health, Absci, GemPharmatech, Vazyme Biotech, Suzhou Sepax Technologies, VCANBIO, Takara Bio, SEEGENE. |
| What is the current market cap of Personalis? | Personalis' current market cap is $1B. |
| What is the current revenue of Personalis? | Personalis' last 12 months revenue is $74M. |
| What is the current revenue growth of Personalis? | Personalis revenue growth (NTM/LTM) is 27%. |
| What is the current EV/Revenue multiple of Personalis? | Current revenue multiple of Personalis is 12.3x. |
| Is Personalis profitable? | No, Personalis is not profitable. |
| What is the current EBITDA of Personalis? | Personalis has negative EBITDA and is not profitable. |
| What is Personalis' EBITDA margin? | Personalis' last 12 months EBITDA margin is (123%). |
| What is the current EV/EBITDA multiple of Personalis? | Current EBITDA multiple of Personalis is (10.0x). |
| How many companies Personalis has acquired to date? | Personalis hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Personalis has invested to date? | Personalis hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Personalis
Lists including Personalis
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.